Authors' objectives: To assess the effectiveness, safety, economic and organisational implications of Rezūm therapy for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH)

Authors' results and conclusions: Based on retrievable evidence, Rezūm therapy had shown to improve urologic symptoms and quality of life as early as six months post procedure and remained durable through five years follow-up. In comparison to medical monotherapy, Rezūm demonstrated more significant improvement in lower urinary tract symptoms and a slower rate of clinical progression among BPH patients. Through an indirect comparison between MIST procedures, Rezūm therapy displayed comparable effectiveness outcomes to UroLift, but was inferior to Aquablation at two years follow- up. The TURP procedure (gold standard) was found to cause a more significant improvement in urologic symptoms and quality of life compared to Rezūm therapy at different time intervals up to two years of follow up periods. Application of Rezūm therapy for large-sized prostates showed comparable improvement with small-sized prostates. The occurrence rate of adverse events was high while Rezūm therapy was shown to be a cost-saving procedure in comparison to other MISTs and invasive BPH surgeries (HoLEP and TURP).

Authors' recommendations: Rezūm therapy may be used as alternative treatment option for moderate to severe LUTS in men with BPH.

Authors' methods: A comprehensive search was conducted on the following databases without any restriction on publication language and publication status. The Ovid interface: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non- Indexed Citations and Daily 1946 to September 28, 2021; Cochrane Library 2021 Issue 8 - Cochrane Database of Systematic Reviews – Cochrane Central Register of Controlled Trials (CENTRAL). Searches were also run in PubMed. Google was used to search for additional web-based materials and information. Additional articles were identified from reviewing the references of retrieved articles. Last search was conducted on 30 September 2021.

Authors' identified further research: None

Project Status: Completed

Year Published: 2021

URL for published report: https://www.moh.gov.my/index.php/database_stores/store_view_page/30/385

Requestor: Ministry of Health

English language abstract: An English language summary is available

Publication Type: Mini HTA

Country: Malaysia

Organisation Name: Malaysian Health Technology Assessment

Contact Address: Malaysian Health Technology Assessment Section, Ministry of Health Malaysia, Federal Government Administrative Centre, Level 4, Block E1, Parcel E, 62590 Putrajaya Malaysia Tel: +603 8883 1229

Contact Name: htamalaysia@moh.gov.my

Contact Email: htamalaysia@moh.gov.my

Copyright: Malaysian Health Technology Assessment Section (MaHTAS)